Skip to main content

5α-Reductase Inhibitors (5-ARIs)

Clinical role​

Finasteride and dutasteride reduce conversion of testosterone to dihydrotestosterone (DHT). In men with symptomatic BPH and an enlarged prostate, they gradually reduce gland volume and lower the risk of acute retention and BPH surgery. They are a long-term option; clinically meaningful symptom benefit usually requires several months. They do not provide immediate relief of retention or replace evaluation of another cause of LUTS.[1][2]

EAU 2026 recommends 5-ARIs for moderate-to-severe LUTS with increased progression risk, using prostate volume >40 mL as an example. AUA 2026 recommends offering a 5-ARI for symptoms when estimated prostate volume is >30 cc and/or PSA >1.5 ng/mL (Moderate, Grade A); reducing progression in this enlarged-prostate group is a Clinical Principle. The alpha-blocker/5-ARI combination uses the same enlargement criteria (Moderate, Grade B). These are selection guides rather than proof that every man above one threshold needs treatment. PSA must first be interpreted in its clinical context.[3][4]

Agents and administration​

AgentAdult BPH regimenImportant formulation and pharmacology points
Finasteride (Proscar)5 mg orally once daily, with or without foodPrimarily type 2 inhibition. The 1-mg alopecia product is a separate indication/dose. No renal dose adjustment; use caution with liver dysfunction.
Dutasteride (Avodart)0.5 mg orally once daily, with or without foodType 1 and 2 inhibition. Swallow capsules whole; do not open or chew. No renal adjustment. Hepatic impairment has not been studied adequately; exposure may increase. The approximately five-week terminal half-life means effects/exposure do not disappear immediately after stopping.
Dutasteride/tamsulosin (Jalyn)0.5/0.4 mg once daily, about 30 minutes after the same mealSwallow whole; the tamsulosin component adds orthostasis, interactions, ejaculation effects and IFIS precautions. See the alpha-blocker hub.

Dosing and organ-function information are from the US labels.[1][2][5] Dutasteride lowers circulating DHT more than finasteride, but this is not proof of better clinical outcomes. In EPICS, 1,630 men randomized to the two agents had similar prostate-volume, symptom and flow improvements over 12 months; the primary endpoint was prostate volume, not long-term retention or surgery.[6]

Finasteride has no established clinically important pharmacokinetic interactions in its label. Use caution with chronic potent CYP3A4 inhibition and dutasteride; combination products require review of both ingredients. Adding an alpha-blocker can increase adverse effects even when there is no major pharmacokinetic interaction.[1][2][5]

What the major BPH trials establish​

EvidencePopulation and interpretation
MTOPS3,047 men, mean follow-up 4.5 years. Doxazosin, finasteride and combination reduced composite clinical progression by 39%, 34% and 66%, respectively, versus placebo. The composite was largely symptom worsening; only finasteride and combination reduced retention and invasive therapy. Do not read the 66% as a reduction in each complication.[7]
CombAT4,844 men with IPSS ≥12, prostate volume ≥30 mL and PSA 1.5–10 ng/mL; four years, no placebo arm. Dutasteride/tamsulosin improved symptoms and reduced overall clinical progression more than either alone. For the primary AUR-or-surgery endpoint, combination was superior to tamsulosin but not significantly superior to dutasteride.[8]

Combination therapy can be considered initially in a symptomatic patient with substantial progression risk; failure of alpha-blocker monotherapy is not a prerequisite. Balance expected benefit against sexual effects, treatment burden and the time needed for the 5-ARI to work. Treatment is generally prolonged while useful, but it is not automatically lifelong after effective surgery or a change in goals.[3][4]

PSA interpretation: use the drug-specific timeline and the trend​

5-ARIs commonly lower PSA by about half, including when prostate cancer is present. Record the drug, start date and adherence wherever PSA is interpreted.[1][2]

Product labelSerial measurementsComparing one value with untreated reference ranges
Finasteride 5 mgEstablish a new baseline after at least six months; monitor periodicallyAfter ≥6 months, double the observed value for comparison
Dutasteride 0.5 mgEstablish a new baseline after at least three months; monitor periodicallyAfter ≥3 months, double the observed value for comparison

Doubling is an approximate interpretation adjustment, not the patient's exact untreated or “true” PSA. It does not replace the trend: evaluate a confirmed increase from the on-treatment nadir, even if the number falls within an untreated normal range. Review adherence and other explanations; an isolated fluctuation is not automatically cancer. Percent free PSA generally does not require the same adjustment.[1][2]

The 2019 Veterans Affairs cohort of 80,875 men with prostate cancer associated prediagnostic 5-ARI use with longer diagnostic delays and worse cancer-specific outcomes. This observational finding reinforces the need to recognize PSA suppression; it does not establish that the medicine itself caused aggressive cancer or that missed PSA adjustment was the sole cause.[9]

Sexual effects, fertility and breast symptoms​

Discuss erectile dysfunction, reduced libido, lower ejaculate volume and breast tenderness/enlargement before treatment. Frequency varies by product, dose, follow-up and whether an alpha-blocker is also used. Fewer newly reported sexual adverse events in later trial years does not prove that every existing symptom resolves.[1][2]

Both labels acknowledge reports of sexual problems persisting after discontinuation, with frequency and the independent drug contribution difficult to determine. Take persistent symptoms seriously and assess other contributors rather than promising reversibility or assigning an inevitable permanent syndrome.[1][2]

Semen changes can matter when fertility is a priority. The dutasteride label describes a small healthy-volunteer study (27 treated, 23 placebo) with reduced total sperm count, volume and motility; mean sperm count had not returned to baseline at 24 weeks after treatment. Average normal-range values do not establish safety for an individual with impaired fertility. Finasteride has postmarketing infertility/poor-semen-quality reports, including improvement after withdrawal. Consider a medication and semen assessment when conception is difficult.[1][2]

Evaluate new breast lumps, nipple discharge or other concerning changes. Male breast cancer has been reported after marketing; a causal relationship is not established.[1][2]

Mood and suicidality: current regulatory distinctions​

The US Proscar label lists depression and suicidal ideation in postmarketing experience. The reviewed US Avodart label lists depressed mood; it should not be described as identical wording for both drugs.[1][2]

EMA's 2025 review confirmed suicidal ideation as an adverse effect of oral finasteride 1 mg and 5 mg, with unknown frequency and most reports arising from alopecia use. It found no direct link for dutasteride and recommended a precautionary warning because of the shared mechanism.[10]

The May 11, 2026 MHRA update reinforces baseline mood-history assessment and regular review for psychiatric and sexual effects. Its instructions distinguish stopping finasteride 1 mg and promptly contacting the prescriber if depression/suicidal thoughts develop from seeking prompt medical advice for finasteride 5 mg or dutasteride. Immediate danger or self-harm requires emergency care regardless of drug or dose.[11]

Large observational cohorts have associated 5-ARI use with depression; suicide estimates have been less consistent. Welk's 2017 study was a matched cohort, not a case-control study. The Swedish cohort's early dementia association diminished with longer exposure, raising detection/confounding concerns. Neither observational association nor a proposed neurosteroid mechanism proves a specific cause in an individual patient.[12][13]

Prostate cancer: prevention trials do not remove the label warning​

PCPT and REDUCE reduced biopsy-detected prostate cancer overall, mainly lower-grade disease. Neither drug is FDA-approved for cancer prevention. Current US labels retain warnings concerning Gleason 8–10 cancers: finasteride 1.8% versus placebo 1.1% in PCPT, and dutasteride 1.0% versus 0.5% in REDUCE.[1][2]

Do not conflate those warnings with every Gleason ≥7 comparison. In REDUCE, overall Gleason 7–10 counts were similar, while a Gleason 8–10 imbalance emerged particularly in years 3–4. Smaller prostate volume and improved detection can contribute to the findings, but a blanket statement that bias conclusively explains every high-grade signal goes beyond the labels and evidence.[14]

Long-term evidence is reassuring about mortality, with uncertainty:

  • At median 18.4-year follow-up in PCPT, there were 42 prostate-cancer deaths among 9,423 eligible finasteride-assigned men and 56 among 9,457 placebo-assigned men, HR 0.75 (95% CI 0.50–1.12). This did not establish a mortality reduction.[15]
  • A 2023 meta-analysis of 11 studies and more than 3.2 million men found no statistically significant mortality association, adjusted HR 1.04 (95% CI 0.80–1.35). Mixed study designs and confounding limit causal conclusions; “not significant” is not proof of zero risk.[16]

Use these findings for balanced BPH counseling alongside careful PSA surveillance, not to promote routine chemoprevention or dismiss the current high-grade warning.

Other uses and perioperative decisions​

  • Prostatic hematuria: after excluding other causes, a 5-ARI may help refractory bleeding attributed to an enlarged prostate. This AUA 2026 Expert Opinion option does not replace hematuria evaluation or acute clot-retention management; do not impose the BPH symptom-response timeline on bleeding control.[4]
  • CP/CPPS: AUA 2025 permits 5-ARIs when there are coexisting voiding symptoms from BPH or enlargement (expert opinion). They are not general-purpose pelvic-pain treatment.[17]
  • Surgery: UKCPA advises continuing finasteride/dutasteride perioperatively. The old instruction to stop two weeks before prostate surgery to improve bleeding control was unsupported. After effective TURP and successful catheter removal, reassess whether the medication is still needed; no universal 2–4-week restart rule applies.[18][19]

Pregnancy, handling and donation​

Pregnancy exposure can disrupt development of male external genitalia. These BPH products are not indicated for women or children. A person who is or may be pregnant should avoid crushed/broken finasteride tablets and dutasteride capsules, especially leaking capsules; wash exposed skin promptly. Intact finasteride coating prevents contact during ordinary handling. Current narrative pregnancy labeling replaces the old letter-category shorthand.[1][2]

Very small quantities occur in semen; do not turn this into a universal US-label condom requirement for both products. Discuss pregnancy exposure using the applicable product and jurisdiction's labeling. No blood donation during dutasteride treatment or for at least six months after the last dose; check the blood service's deferral rules for other products.[1][2]

See Also​

References​

1. PROSCAR (finasteride 5 mg). US prescribing information. Source.

2. AVODART (dutasteride). US prescribing information. Source.

3. European Association of Urology. Non-neurogenic Male LUTS Guideline, 2026. 5-ARI and combination-treatment sections. Source.

4. Goueli R, et al. Management of LUTS attributed to BPH: AUA Guideline (2026), Part II—Medical Management. Source.

5. JALYN (dutasteride/tamsulosin). US prescribing information. Source.

6. Nickel JC, et al. Comparison of dutasteride and finasteride for treating BPH: EPICS. BJU Int. 2011. Source.

7. McConnell JD, et al. Long-term doxazosin, finasteride and combination therapy: MTOPS. N Engl J Med. 2003. Source.

8. Roehrborn CG, et al. Four-year CombAT results. Eur Urol. 2010. Source.

9. Sarkar RR, et al. Association of treatment with 5-ARIs with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019. Source.

10. European Medicines Agency. Finasteride/dutasteride referral and measures to minimize suicidal thoughts, 2025. Source.

11. MHRA. Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. May 11, 2026. Source.

12. Welk B, et al. Association of suicidality and depression with 5-ARIs. JAMA Intern Med. 2017. Source.

13. Garcia-Argibay M, et al. Association of 5-ARIs with dementia, depression and suicide. JAMA Netw Open. 2022. Source.

14. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer: REDUCE. N Engl J Med. 2010. Source.

15. Goodman PJ, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380:393–394. Source.

16. Baboudjian M, et al. Association between 5-ARIs and prostate cancer mortality: systematic review and meta-analysis. JAMA Oncol. 2023. Source.

17. American Urological Association. Male Chronic Pelvic Pain Guideline, 2025. Statement 19. Source.

18. UKCPA. Handbook of Perioperative Medicines: finasteride. Source.

19. UKCPA. Handbook of Perioperative Medicines: dutasteride. Source.